13F Holdings
中文EN

HCM HUTCHMED (China) Ltd

Pharmaceutical Preparations · Nasdaq · SEC CIK 1648257

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-13.0%
TTM net income YoY1,111.0%
TTM EPS YoY1,200.0%
Revenue 3-yr CAGR8.8%
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-7.1%
Net margin83.3%
FCF margin-14.4%
EBITDA margin-4.7%

Returns

ROE45.7%
ROA30.2%
ROIC (approx.)-3.5%
Asset turnover0.36x

Leverage & solvency

Liabilities / assets28.6%
Debt / equity0.08x
Current ratio4.96x
Interest coverage-13.67x

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio34.5%
Payout ratio—
Capex / revenue2.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$548.51M$630.20M$838.00M$426.41M$356.13M
Cost of revenue$336.35M$348.88M$384.45M$311.10M—
Gross profit$212.16M$281.32M$453.55M$115.31M—
R&D expense$148.29M$212.11M$302.00M$386.89M$299.09M
SG&A expense$66.72M$64.30M$79.78M$92.17M$89.30M
Operating income-$39.16M-$43.70M$18.38M-$407.69M-$328.32M
Interest expense$2.87M$2.87M$759,000$652,000$592,000
Pretax income$498.69M-$1.11M$58.31M-$410.42M-$215.74M
Income tax$63.61M$7.19M$4.51M-$283,000$11.92M
Net income$456.91M$37.73M$100.78M-$360.83M-$194.65M
EBITDA-$25.85M-$31.36M$26.58M-$399.03M-$321.13M
EPS (basic)0.530.040.12-0.43-0.25
EPS (diluted)0.520.040.12-0.43-0.25
Weighted avg. shares (diluted)872.89M872.83M869.20M847.14M792.68M
Banking
Deposits$1.68M$1.63M$1.56M$3.62M$2.11M
Balance sheet
Cash & equivalents$71.33M$153.96M$283.59M$313.28M$377.54M
Short-term investments$1.30B$682.15M$602.75M$317.72M$634.16M
Receivables$126.75M$155.54M$116.89M$97.99M$83.58M
Inventory$41.13M$50.40M$50.26M$56.69M$35.76M
Current assets$1.57B$1.07B$1.10B$839.89M$1.21B
PP&E, net$94.62M$92.50M$99.73M$75.95M$41.27M
Goodwill$3.11M$2.99M$3.06M$3.14M$3.38M
Intangibles$8.94M—$21,000$85,000$163,000
Total assets$1.75B$1.27B$1.28B$1.03B$1.37B
Current liabilities$315.77M$376.56M$403.03M$353.90M$311.66M
Short-term debt$24.97M$23.37M$31.16M—$26.91M
Long-term debt$68.19M$59.43M$48.19M$18.10M$26.91M
Total debt$93.16M$82.81M$79.34M$18.10M$53.81M
Total liabilities$501.83M$502.34M$536.39M$392.57M$333.15M
Shareholders' equity$1.24B$759.93M$730.54M$610.37M$986.89M
Net debt$21.83M-$71.15M-$204.25M-$295.17M-$323.73M
Cash flow statement
Operating cash flow-$64.66M$497,000$219.26M-$268.60M-$204.22M
Capital expenditure$14.15M$17.93M$32.61M$36.66M$16.40M
Free cash flow-$78.81M-$17.44M$186.65M-$305.26M-$220.62M
Investing cash flow-$29.41M-$96.06M-$291.14M$296.59M-$306.32M
Financing cash flow$7.84M-$30.67M$48.66M-$82.76M$650.03M
Depreciation & amortization$13.31M$12.34M$8.21M$8.66M$7.19M
Share buybacks—$36.06M$9.07M$48.08M$27.31M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.